Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

“The acquisition of Biotheus builds on our successful ongoing collaboration on BNT327/PM8002 and other investigational ...

BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...

The main difference is BNT327 targets PD-L1 while ivonescimab engages PD-1. On an earnings call last week, BioNTech CEO Ugur ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Good day and thank you for standing by. Welcome to the Roivant second-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I ...

BlackSky Technology Inc. ("BlackSky" or the "Company") (NYSE: BKSY) announced results for the third quarter ended September 30, 2024. Third Quarter Financial Highlights: Revenue ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) has released its third-quarter 2024 financial results, showcasing significant ...